MOG and myeloid sarcoma: Therefore, before introducing treatment for MS, it is crucial to the first rule out NMO by performing serological tests for anti-AQP4 and anti-myelin oligodendrocyte glycoprotein (MOG) presence in all patients with features characteristic for NMO [83].